Cancer Treatments of the Future
Dr. William Makis
In 2025, AI-driven mRNA cancer vaccines promised $500 billion investment, yet mRNA technology is ineffective and dangerous; instead, AI identifies repurposed antiparasitics like ivermectin, mebendazole, and fenbendazole, proven in preclinical cancer research across 28 tumor types and multiple mechanisms, including cancer stem cell inhibition and sugar uptake blockade. These affordable off-patent drugs offer significant cancer benefits, enhanced chemotherapy synergy, fewer side effects, and global accessibility, threatening lucrative cancer drug markets dominated by companies like Pfizer, Merck, and J&J, which suppress these alternatives to preserve profits.
"I believe that repurposed drugs like ivermectin, fenbendazole, and mebendazole are the future. Because they give power back to the people, allowing them to reclaim control of their health and manage cancer for pennies on the dollar."
Summary
- AI-driven mRNA cancer vaccines promised $500B but mRNA platform labeled ineffective and dangerous by speaker. - Repurposed drugs like ivermectin, mebendazole, fenbendazole show promise for cancer treatment, are cheap, safe, and widely available. - These drugs have multiple anticancer mechanisms, can shrink tumors, reduce chemo side effects, and even treat benign tumors. - Big Pharma profits hugely from costly cancer drugs, suppressing cheap alternatives to maintain control and revenue. - Repurposed antiparasitics empower patients worldwide to manage cancer affordably, challenging centralized, expensive medical systems.
Article
Repurposed antiparasitics could transform cancer treatment, claims controversial oncologist
At international symposium, Dr. William Makis presents evidence that inexpensive off-patent drugs show promise where multi-billion dollar treatments fail
Common antiparasitic medications could revolutionise cancer treatment at a fraction of the cost of conventional therapies, according to controversial research presented at an international health symposium in El Salvador this week.
Dr. William Makis, an oncologist who runs a global telehealth practice, told attendees at the Reclaiming Health & Longevity Symposium that medications like ivermectin, mebendazole, and fenbendazole – drugs typically used to treat parasitic infections – have demonstrated remarkable efficacy against numerous cancer types while costing pennies compared to mainstream treatments.
"If you can treat cancer for fifty dollars a month instead of five hundred thousand dollars, it would blow up the pharmaceutical industry, and that's what they can't stand," Dr. Makis said during his Tuesday presentation titled "Cancer Treatments of the Future."
Challenging the AI-pharmaceutical complex
Dr. Makis began by criticising a January 2025 White House initiative that committed $500 billion to AI-generated mRNA cancer vaccines, calling the technology "a fraud" that "doesn't work" and is "extremely dangerous."
Despite this criticism of AI-driven pharmaceutical development, Dr. Makis acknowledged artificial intelligence's value as a research tool. He noted that AI systems already identify repurposed antiparasitic drugs as among the most promising treatments for terminally ill cancer patients when analysing existing research literature.
"AI can be used as a tool to fine-tune our knowledge and sift through thousands of papers, but we should not rely on it completely," he explained.
Repurposing established medications
The central argument of Dr. Makis's presentation focused on medications developed for parasitic conditions that have shown anticancer properties. These drugs have established safety records spanning decades, known pharmacokinetic profiles, and are typically off-patent and inexpensive.
According to research cited by Dr. Makis, these medications have demonstrated anticancer effects across 28 different tumor types through multiple mechanisms, including shutting down cancer cell proliferation pathways and blocking cancer stem cells – cells that often survive conventional chemotherapy.
"Cancer drug companies want to keep making money, but repurposed antiparasitic drugs are cheap, effective, and have been shown to kill cancer cells through multiple mechanisms," Dr. Makis told the audience.
He highlighted published preclinical research showing that ivermectin blocks cancer stem cells, while fenbendazole disrupts glucose uptake by cancer cells, essentially cutting off their fuel supply.
Patient outcomes
Drawing from his telehealth practice, which he described as "the world's largest ivermectin cancer clinic" with over 7,200 patients treated globally, Dr. Makis shared several case studies. These included a 94-year-old man whose aggressive leg lymphoma reportedly disappeared after five months of ivermectin treatment and an Australian woman with stage four breast cancer that had metastasised to her skeleton, which allegedly resolved within six weeks of starting a combination of ivermectin and fenbendazole.
"About seventy-five to eighty percent of cancer patients treated with repurposed drugs have some kind of benefit; some even clear their cancer from stage four to cancer free," he claimed.
He also suggested these medications reduce side effects from conventional treatments like chemotherapy and radiation by dampening inflammation and fatigue, allowing patients to better tolerate standard therapies.
The economics of cancer care
Dr. Makis contrasted the cost of current cancer treatments – ranging from $200,000 to $700,000 per patient – with repurposed medications costing as little as 50 cents to $5 per dose. He argued that this dramatic price difference explains why pharmaceutical companies might resist research into these alternatives.
"The decentralization of medicine happened when people took control of their health using cheap, readily available drugs without needing a doctor," he said, drawing parallels to the use of repurposed drugs during the COVID-19 pandemic.
He alleged that pharmaceutical companies with financial interests in expensive cancer treatments actively suppress research on these alternatives, noting that many companies now developing cancer drugs once held patents on the very antiparasitic medications he promotes.
Future directions
The presentation concluded with Dr. Makis predicting that repurposed drugs represent the future of cancer care, potentially giving patients more agency over their treatment while dramatically reducing costs.
He mentioned emerging approaches in this field, including new delivery methods such as nanoparticles and intranasal administration, as well as potential synergies with electromagnetic frequencies and other complementary treatments.
The Reclaiming Health & Longevity Symposium continues through Wednesday in El Salvador, featuring speakers addressing various aspects of health independence and alternative approaches to disease management.
While Dr. Makis's claims have generated significant interest among attendees, mainstream oncology organisations maintain that conventional cancer treatments backed by large-scale clinical trials remain the standard of care, and caution patients to consult with their healthcare providers before pursuing alternative treatments.
Part of Reclaiming Health & Longevity Symposium